Evidence map›Paper›PMID 41395870›Full record

ArticleCancer medicine2025

Trends in Pleural Mesothelioma Incidence and Survival in Metropolitan and Nonmetropolitan Areas in the United States.

Alexander J Didier, Charlotte Lennox, Mingjia Li, Jinesh Gheeya, Asrar Alahmadi, Jacob Kaufman, Regan Memmott, Kai He, Peter Shields, Christian Rolfo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alexander J DidierDepartment of Medicine, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Charlotte LennoxDepartment of Medicine, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Mingjia LiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-3910-4179
Jinesh GheeyaDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Asrar AlahmadiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Jacob KaufmanDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Regan MemmottDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Kai HeDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Peter ShieldsDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Christian RolfoDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
David P CarboneDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Carolyn PresleyDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-2607-5639
Dwight OwenDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Logan RoofDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-9362-7851

Funding

Ohio State University
6 · The paper itself

Abstract

introductionPleural mesothelioma (PM) is a rare, aggressive cancer with significant variation in incidence based on geographic factors. Previous studies have highlighted cancer survival disparities between metropolitan and nonmetropolitan populations for other cancers; this data is largely unreported for PM. We aimed to compare incidence trends and cancer-specific survival (CSS) between metropolitan and nonmetropolitan areas in the United States using the Surveillance, Epidemiology, and End Results (SEER) database.

methodsWe analyzed SEER 18 registries for patients aged ≥ 20 diagnosed with PM between 2004 and 2021. Incidence rates, CSS, and demographic and clinical characteristics were compared between metropolitan and nonmetropolitan areas. Incidence rate ratios (IRRs) were calculated using the Tiwari method. Joinpoint regression was used to assess temporal trends, while Kaplan-Meier and Cox proportional hazard models analyzed survival outcomes.

resultsA total of 8519 PM cases were identified, with 89.3% in metropolitan areas. Nonmetropolitan patients were more likely to be non-Hispanic Black and had lower chemotherapy (p = 0.031) and surgery (p < 0.001) rates. The incidence rate in metropolitan areas declined from 1.4 in 2004 to 0.8 in 2021, while nonmetropolitan areas saw a stable incidence until 2017, followed by a decline to 0.5 in 2021. Metropolitan areas had significantly higher CSS, with 50.3% 1-year CSS by 2020, compared to 27.7% in nonmetropolitan areas. Multivariate analysis indicated a higher hazard of death in nonmetropolitan areas (HR = 1.18, p < 0.001).

conclusionSignificant disparities in PM outcomes between metropolitan and nonmetropolitan areas were revealed. Although both regions experienced a decline in incidence over time, survival outcomes remained worse in nonmetropolitan areas. Patients in nonmetropolitan areas were also less likely to receive chemotherapy and surgery, further contributing to the survival gap. These findings highlight the need for targeted interventions to improve treatment access and enhance survival for nonmetropolitan patients with PM.

Indexed as

MesotheliomaMesothelioma, MalignantPleural NeoplasmsAdultAgedFemaleHumansIncidenceMaleMiddle AgedSEER ProgramSurvival RateUnited StatesUrban Population

Identifiers

PMID41395870
PMCPMC12704024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.